CORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082
|
|
- Ira White
- 6 years ago
- Views:
Transcription
1 CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from CYP genes, this panel also tests other - genes which contribute to drug response and clearance. OPRM1 controls production of the µ-opioid receptor, which is the primary site of action for opioid drugs. SLCO1B1 translates into a protein that spans the cell membrane and transports drugs from blood into liver cells assisting in their clearance. COMT encodes an enzyme that is involved in the inactivation of catecholamine neurotransmitters and is hence associated with many psychotropic disorders. A total of 60 allelic variants of these enzymes are tested and analyzed to predict an individual s drug metabolizing potential. Appropriate positive and negative internal controls are included in each reac- - tion in order to ensure precision and data quality. Based on the patient s genotype, Castle relays the CPIC's dosage recommendations for select drugs. Specimen OraCollect (OC-100) swab. Please provide a separate swab for each panel ordered. Storage Room temperature, out of intense light. Do not freeze or refrigerate specimens. Instructions Please follow the instructions provided with the saliva collection kit. Cause of Rejection Insufficient/Contaminated DNA recovery Purpose Variation in drug-metabolizing enzymes, transporter proteins, and receptors can influence patients responses to drugs. This variation is usually caused by genetic polymorphisms. Clinical effects of these polymorphisms depend on the drug and the specific genetic changes involved. Genotyping helps in predicting the right dosage regimen for drugs, reducing the chance of drug-induced adverse reactions and possible therapeutic failure of prodrugs. - Who should take this test? Patients who are currently using, or planning to use, a medication whose dosage or efficacy is affected by variation in the above-listed genes. Methodology and Limitations TaqMan fluorescent probe based assays assessed by real-time polymerase chain reaction (qpcr). This is not a sequencing test and will only detect the variations listed in these documents; other, rare variations may also be present. Additional information Apart from patient s genotype, the activity of CYP enzymes is also influenced by a patient s physiological state, diet, and other concomitant medications.
2 C YP2D6 Genetic Variants and their s *1X2 Duplication in *1 Increased *3 rs Inactive *4 rs , rs Inactive *4X2 Duplication in *4 Unpredictable *5 CYP2D6 is entirely absent Inactive in this allele. *6 rs Inactive *7 rs Inactive *8 rs (A) Inactive *10 rs Decreased *11 rs Inactive *12 rs Inactive *14 rs (T) Inactive *41 rs Inactive rs rs Inactive rs rs Decreased rs rs Inactive rs rs Inactive *4-like X2 Duplication in *4-like Cannot define *1 X2 Duplication in *1 Increased rs X2 Duplication in rs Increased CYP2D6 CYP2D6 metabolizes a significant number of clinically-used medications, including select opioids, antidepressants, anti-psychotics, beta blockers, and antiarrhythmics. Based on CYP2D6 genotype, the following phenotype categories can - be predicted: or close-to-normal CYP2D6 enzyme activity. Patients with this phenotype have two normal alleles, one normal and one decreased activity allele, one normal and one inactive allele, or two decreased function alleles. Somewhat reduced CYP2D6 enzyme activity. Patients in this category have one decreased activity and one inactive allele. This phenotype is associated with two inactive alleles. Poor metabolizers have diminished capacity to eliminate drugs and so are at increased risk of drug-induced side effects. Also, poor metabolizers have reduced potential to activate prodrugs, which might result in therapeutic failure in some cases. Ultrarapid metabolizer This category indicates the presence of an extra copy of CYP2D6, which results in higher-than-normal enzyme activity. The patient's increased ability to eliminate drugs might result in diminished or no therapeutic activity. At the same time, these patients will rapidly activate prodrugs, putting them at increased risk of adverse drug reaction.
3 C YP2C19 Genetic Variants and their s *2 rs Inactive *2B rs , rs Inactive *3 rs Inactive *4 rs Inactive *5 *6 *8 *9 *10 *17 rs (insg) rs Inactive rs Inactive rs Inactive rs Decreased rs rs rs (insg) Decreased Increased Decreased CYP2C19 This enzyme metabolizes 10-15% of all clinically relevant drugs including diazepam, carisoprodol, and some anticonvulsants, tricyclic antidepressants, antiplatelet agents, and proton pump inhibitors. Based on CYP2C19 genotype, the following phenotype categories can be predicted: CYP2C19 enzyme activity. Patients with this pheno-type have two normal alleles. Partially reduced CYP2C19 enzyme activity. Patients in this category have one normal and one inactive allele. This phenotype is associated with two inactive alleles. Poor metabolizers have diminished capacity to eliminate drugs, which increases the risk of drug-induced side effects due to slow elimination of drugs from the body. These patients are also prone to therapeutic failure of prodrug medications due to slow activation of the drugs. Rapid/Ultrarapid metabolizer The CYP2C19*17 variant causes an increase in the rate of CYP2C19 enzyme formation, which results in higher-than-normal enzyme activity. The patient's increased ability to eliminate drugs might result in diminished or no therapeutic activity. At the same time, these patients will rapidly activate prodrugs, putting them at increased risk of adverse drug reaction.
4 C YP2C9 Genetic Variants and their s *2 rs Inactive *3 rs Inactive *5 rs Inactive *7 rs Inactive *8(A) rs (a) *8(T) rs (t) Inactive *10 rs Decreased *11 rs Decreased *13 rs Decreased *15 rs Inactive CYP2C9 CYP2C9 plays a major role in metabolizing drugs with narrow therapeutic indices such as warfarin and phenytoin. Most nonsteroidal anti-inflammatory drugs (NSAIDs) are also metabolized by CYP2C9. Based on CYP2C9 genotype, the following phenotype categories can be predicted: CYP2C9 enzyme activity. Patients in this category have two normal alleles. Partially reduced CYP2C9 enzyme activity. Patients in this category have one normal and one inactive allele. This phenotype is associated with two inactive alleles. Poor metabolizers have reduced enzymatic activity, leading to reduced activation of prodrugs and slowed clearance of other drugs.
5 C YP3A4 Genetic Variants and their s *2 rs Decreased *3 rs Decreased *4 rs Decreased *5 rs Decreased *6 rs Decreased *11 rs Decreased *12 rs Decreased *13 rs Decreased *15 rs Decreased *16 rs Decreased *17 rs Decreased rs rs Decreased CYP3A4 CYP3A4 is responsible for the metabolism of approximately 50-60% of all currently-used clinical drugs, including buprenorphine, citalopram, escitalopram, levomilnacipran, buspirone, mirtazapine, cyclophosphamide, isophosphamide, tamoxifen, haloperidol, aripiprazole, iloperidone, lurasidone, quetiapine, ziprasidone, guanfacine, modafinil, and cyclobenzaprine, as well as several benzodiazepines, mood stabilizers, opioids, and proton pump inhibitors. Based on CYP3A4 genotype, the following phenotype categories can be predicted: CYP3A4 enzyme activity. This phenotype includes patients with two normal alleles. Partially reduced CYP3A4 enzyme activity. Patients in this category have one normal and one decreased-function allele. This phenotype is associated with two decreased-function alleles. s have reduced enzymatic activity, leading to reduced activation of prodrugs and slowed clearance of other drugs.
6 C YP3A5 Genetic Variants and their s *1A - Full function *2 rs Decreased *2, *3C rs776746, rs Inactive *3B rs776746, rs Inactive *3C rs Inactive *3D rs776746, rs Inactive *6 rs Inactive *7 rs Inactive rs rs Decreased CYP3A5 CYP3A5 is very similar to CYP3A4 in structure and function, but it is only expressed in a limited number of individuals. Having functional CYP3A5 can speed the metabolism of the - enzyme s target drugs. Based on CYP3A5 genotype, the following phenotype categories can be predicted: Full CYP3A5 enzyme activity. This phenotype indicates two active alleles. Partially reduced CYP3A5 enzyme activity. Patients in this category have one normal and one inactive allele. This phenotype is associated with two inactive alleles. Poor metabolizers have low enzymatic activity, leading to reduced activation of prodrugs and slowed clearance of other drugs.
7 C YP2B6 Genetic Variants and their s *5 rs Decreased *9 rs Decreased *19 rs Decreased CYP2B6 CYP2B6 is responsible for the biotransformation of members of several different categories of drugs, including antidepressants, antiplatelet drugs, anti-hiv, anticancer drugs, anesthetics, and analgesics. High inter-individual variation (about fold) has been reported in CYP2B6 expression. Genetic polymorphism in the CYP2B6 gene can influence drug response and drug-mediated toxicity. Based on CYP2B6 genotype, the following phenotype categories can be predicted: CYP2B6 enzyme activity. This phenotype includes patients with two normal alleles. Partially reduced CYP2B6 enzyme activity. Patients in this category have one normal and one decreased-function allele. This phenotype is associated with two decreased-function alleles. s have reduced enzymatic activity, which can lead to reduced inactivation of the drugs and hence influence their activity.
8 C OMT Genetic Variants and their s rs6269 rs4633 rs4818 rs4680 G C G G activity A T C A Intermediate activity A C C G Low activity COMT Catechol O-methyl transferase (COMT) is a phase II metabolizing enzyme, primarily responsible for inactivating catecholamine neurotransmitters like dopamine, norepinephrine, and epinephrine. COMT maintains appropriate levels of these neurotransmitters and hence plays a broad regulatory role in brain chemistry. Genetic variation in the COMT gene can lead to abnormal levels of neurotransmitters in the brain and may increase the risk of developing psychiatric disorders. COMT has a role in the modulation of pain and stress, and genetic polymorphism in COMT has been implicated in inter-individual variability in the opioid dose required for the treatment of neuropathic pain. COMT genotype has been associated with some interesting personality traits: people with high levels of COMT activity may perform better stressful conditions while people with lower COMT activity may do better with memory and attention tasks. COMT also metabolizes L-DOPA (levodopa), a synthetic precursor of the neurotransmitter dopamine which is used in the clinical treatment of Parkinson s disease (PD). This is undesirable, and current PD therapy often includes a drug intended to inhibit COMT activity. Based on COMT genotype, the following phenotype categories can be predicted: activity COMT enzyme activity. Intermediate activity Somewhat reduced COMT enzyme activity. Low activity Reduced COMT enzymatic activity, leading to increased levels of catechol neurotransmitters in the brain. Please refer to PharmGKB for more information.
9 OPRM1 Genetic Variants and their s Haplotype rs (A) (wild type) rs (G) Decreased OPRM1 activity Consequence - Decreased analgesic response from opioid therapy. Better response from naltrexone de-addiction therapy. OPRM1 OPRM1 (µ-opioid or mu-opioid receptor 1) is the primary binding site for opioid drugs. Interaction of opioids with the OPRM1 receptor is essential for their analgesic effects. The addictive cravings induced by opioids, alcohol, nicotine, and other abusable substances are also mediated through OPRM1. Naltrexone acts as an OPRM1 antagonist and is used primarily in the management of alcohol and opioid dependence. Polymorphism in the OPRM1 gene can interfere with the receptor protein s ability to interact with drugs and therefore results in inter-individual variability in the sensitivity towards opioids. Mutation in OPRM1 can also influence naltrexone response in addiction therapy. The genetic change known as c.118a>g (or rs ) is one of the best-characterized variants of the OPRM1 gene. Individuals carrying this variant may require comparatively larger or more frequent doses of opioids for pain relief. Also, the presence of this variant makes them more likely to respond to naltrexone therapy. On average, patients carrying this variant will remain abstinent from opioid/alcohol/nicotine abuse for a longer duration and are less likely to relapse. Allelic frequency of rs varies among different ethnic populations. About 14% of the Caucasians and 4% of Africans carry this variation. Please refer to PharmGKB for more information. M
10 SLCO1B1 Genetic Variants and their s *5 rs Decreased SLCO1B1 SLCO1B1 (solute carrier organic anion transporter) is a transmembrane protein, meaning it forms a link between the outside and inside of cells. It mediates the active transport of many endogenous compounds, including bile acids, glucuronide-conjugated steroids, thyroid hormone, prostaglandins, and leukotrienes. SLCO1B1 takes up drugs from the blood and transports them into liver cells for metabolism, indirectly influencing drug clearance. Genetic polymorphism in the SLCO1B1 gene may affect therapeutic efficacy of drugs and is associated with drug-induced toxicity in some cases. For example, statins especially simvastatin are known ligands of SLCO1B1. These cholesterol-lowering drugs induce myopathy in certain populations of patients. Patients with reduced SLCO1B1 activity are more prone to developing statin-induced myopathy. To address this, the FDA has provided dosage recommendations for simvastatin based on patients SLCO1B1 genotype. There is some evidence that adverse reactions to other statins can be similarly predicted, but the magnitude of the effect of genotype is smaller in these cases. Based on rs genotype, the following phenotypes have been defined: activity This phenotype includes two wild type (normal) alleles in rs It predicts normal activity of SLCO1B1 protein and therefore normal risk of statin-induced myopathy. Intermediate activity This phenotype includes one wild type and one mutant allele in rs Patients with this phenotype have intermediate risk of statin-induced myopathy. Low activity The presence of two mutant SLCO1B1 alleles predicts a relatively low level of activity in SLCO1B1 protein. Patients with this phenotype have the highest risk of developing statin-induced myopathy. Please refer to PharmGKB for more information.
Mental Health DNA Insight WHITE PAPER
Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya,.D. ENTAL HEALTH DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D.
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationPharmacogenetics in: Primary Care. Bradley T. Wajda D.O.
Pharmacogenetics in: Primary Care Bradley T. Wajda D.O. Pharmacogenomics Defined Pharmacogenomics uses information about a person s genetic makeup, or genome, to choose the drugs and drug doses that are
More informationPharmacogenomics of Antidepressant Medications
Research Reviews: Pharmacy and Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Pharmacogenomics of Antidepressant Medications Amanpreet Kooner and Inder Sehgal* California Health Sciences, University
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT
PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D. 6777 Nancy Ridge Drive San Diego, CA 92121 US LABORATORY INFO ACCESSION NUBER ACTIVATION CODE SPECIEN
More informationSLCO1B1 Pharmacogenetic Competency
SLCO1B1 Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 Which of the following is not currently a recognized SLCO1B1 phenotype? a) Low function b) Normal function c) Intermediate function
More informationWhite Paper. The Genes Analyzed by the Genecept Assay. May dynacare.ca
White Paper The Genes Analyzed by the Genecept Assay May 2017 888.988.1888 DynacareNext@dynacare.ca dynacare.ca GEN-WP003-v5-052017 INTRODUCTION Dynacare is pleased to present this summary of the genes
More informationCYP2D6 and the oestrogen receptor
Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/cyp2d6-and-the-oestrogenreceptor/ CYP2D6 and the oestrogen receptor The medicinal adjuvant therapy of breast cancer is
More informationComprehensive Drug Information for Smith, John
PATIENT INFORMATION Name: Smith, John DOB: April 22, 1973 Age: 42 Sex: Male SAMPLE Date Collected: March 21, 2016 Date Received: March 21, 2016 Case ID: CARDI16-000001 Source: Buccal Swabs Comprehensive
More informationWhite Paper. The Science Behind the Genecept Assay. January, 2016
White Paper The Science Behind the Genecept Assay January, 2016 Genomind, Inc. 2200 Renaissance Blvd Suite 100 King of Prussia, PA 19406 877.895.8658 www.genomind.com GEN WP003 v3 01182016 INTRODUCTION
More informationPsychiatric Pharmacogenomics: Introduction and Applications
Psychiatric Pharmacogenomics: Introduction and Applications Moises Gaviria, MD Distinguished Professor of Psychiatry University of Illinois at Chicago Medical Director The Institute of Neurobehavioral
More informationGenetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
More informationRight drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing
Right drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing 2 Table of Contents Part One: Pharmacogenetics 101...Slides 4-16 Time Requirement: 20 minutes Part Two:
More information6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES
6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES Ron H.N. van Schaik Dept. Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands 6.1 Introduction In today s medicine, drug therapy represents
More informationPHARMACOGENETICS OF BREAST CANCER
PHARMACOGENETICS OF BREAST CANCER MALGORZATA JAREMKO, PhD Mount Sinai School of Medicine, Department of Genetics and Genomic Sciences Outlines Breast cancer therapeutic situation Pharmacogenetics of antiestrogen
More informationThey deserve personalized treatment
Your patients are unique They deserve personalized treatment New laboratory service offered by STA 2 R is a panel of genetic tests that gives prescribers answers to the clinical questions below. The test
More informationImplementing Pharmacogenetic Testing Into Clinical Laboratories. Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories
Implementing Pharmacogenetic Testing Into Clinical Laboratories Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories Key learning objectives Recognize decisions in implementing pharmacogenetic
More informationObjectives. Clinical Problem. What if there were a way. Pharmacogenomics in Current Practice MEDICINE 12/1/2017
Objectives Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Review the concept of pharmacogenetics and pharmacogenomics
More informationaccesalabs.c
Patient: DOB: Sex: F MRN: JANE DOE (CYP1A1) detoxifies polycyclic aromatic hydrocarbons (PAHs) produced from the combustion of organic materials (exhaust fumes, charbroiled meats, etc.). (CYP1B1) is involved
More informationThe importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
More informationPharmacogenomics in Current Practice. Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy.
Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Objectives Review the concept of pharmacogenetics and pharmacogenomics
More informationOpioid Use: Current Challenges & Clinical Advancements
Opioid Use: Current Challenges & Clinical Advancements Whitney Bergquist, PharmD, MBA, BCPS Acute Care NPPA Conference February 8, 2017 2017 MFMER slide-1 No Disclosures 2017 MFMER slide-2 Objectives Summarize
More informationPharmacogenomics of Medications for Pain and Major Depression: Promise and Peril
Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP Professor of Clinical Sciences Drake University College of Pharmacy and Health
More informationQuetiapine Case 1 Warfarin Jose de Leon, MD
Quetiapine Case 1 Warfarin 1-23-16 Jose de Leon, MD 1. Quetiapine Case 1 J Clin Psychopharm 1999;19:382-3 http://www.ncbi.nlm.nih.gov/pubmed/10440472 Educational Objectives At the conclusion of this presentation,
More informationVariability Due to Genetic Differences
1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Mental Health Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_mental_health_conditions 1/2014 6/2017 6/2018
More informationApplication of Pharmacogenetics Supplementary Worksheet
Application of Pharmacogenetics Supplementary Worksheet Section 1 Health Care Problem Section 2 Drug Metabolism Section 3 Phase I & II metabolism Section 4 Inhibitors and Inducers Section 5 DNA & Drug
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More informationPharmacogenetic Testing in Psychiatry Jose de Leon, MD ( )
Pharmacogenetic Testing in Psychiatry Jose de Leon, MD (12-01-15) Conflicts of Interest (See more details on conflict of interest in the first presentation Training Psychiatrists to Think like Pharmacologists
More informationDeliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing
GA N 668353 H2020 Research and Innovation Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing WP N and Title: WP2 - Towards shared European Guidelines for PGx Lead beneficiary:
More informationGenetic Screening for ADR
Genetic Screening for ADR Mahidol University Faculty of Medicine Siriraj Hospital Manop Pithukpakorn, MD Division of Medical Genetics Department of Medicine concentration Drug level over time toxic optimum
More informationGeneral Discussion 4
General Discussion 4 General Discussion 115 Introduction Psychiatry is considered to be one of the first medical disciplines that will implement pharmacogenetic testing in daily clinical practice. The
More informationMETABOLISM. Ali Alhoshani, B.Pharm, Ph.D. Office: 2B 84
METABOLISM Ali Alhoshani, B.Pharm, Ph.D. ahoshani@ksu.edu.sa Office: 2B 84 Metabolism By the end of this lecture, you should: Recognize the importance of biotransformation Know the different sites for
More informationTwo decades of clinical pharmacogenetic testing - Where do we stand?
Two decades of clinical pharmacogenetic testing - Where do we stand? Marja-Liisa Dahl, MD PhD, Professor Dept of Clinical Pharmacology Karolinska University Hospital/Karolinska Institutet Stockholm, Sweden
More informationPersonalized Medicine in Real Time
LABORATORY OF PERSONALIZED HEALTH LPH Personalized Medicine in Real Time DNA-Guided Clopidogrel (Plavix ) Management Pharmacogenetic Foundations and Case Study 1 Clopidogrel (Plavix ) Leading AntiPlatelet
More informationPHASE I Detoxification: The First Line of Defense
Sex DOB TM DetoxiGenomic Profile PHASE I Detoxification: The First Line of Defense In Phase I detoxification, enzymes, known collectively as the cytochrome P-450 system, use oxygen to modify toxic compounds,
More informationPAIN MEDICATION DNA INSIGHT
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya, M.D. PAIN MEDICATION DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROESSIONAL Nilesh
More information12/10/ Immediate Action, Quest Diagnostics Nichols Institute, Valencia
NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date
More informationPersonalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection. Lindsay S. Elliott, Pharm.D., CGP
Personalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection Lindsay S. Elliott, Pharm.D., CGP Disclosure I, Lindsay Elliott, am a pharmacy consultant for Genelex Corporation in conducting
More informationGenetic Testing for Diagnosis and Management of Mental Health Conditions
Genetic Testing for Diagnosis and Management of Mental Health Conditions Policy Number: Original Effective Date: MM.02.026 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration
More informationPharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC)
Pharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC) Laura Ramsey, PhD Co-Director, Genetic Pharmacology Service Assistant Professor Divisions of Research in Patient
More informationPharmacogenomics and Clinical Practice: Ready for Prime Time? Disclosures. Elder-Friendly Futures Conference 2013 A UW Gerontology Conference
Pharmacogenomics and Clinical Practice: Ready for Prime Time? Manju T. Beier, Pharm D, CGP, FASCP Chief Scientific Officer Natural Molecular Testing Corp. Adjunct Clinical Associate Professor of Pharmacy
More informationPersonalized Medicine & Treatments
Personalized Medicine & Treatments NASCHIP September 14, 2007 Teresa DeLuca, MD, MBA Vice President Department of Personalized Medicine Medco is a registered trademark of Medco Health Solutions, Inc. Pipeline
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationPsychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing
Psychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing CMS NEWEST GUIDELINES CMS will push nursing homes to reduce their use
More information! These tests are not 100% accurate! Positive findings indicates predisposition only.! Results should not be interpreted as diagnostic with treatment
INTERPRETATION ! These tests are not 100% accurate! Positive findings indicates predisposition only.! Results should not be interpreted as diagnostic with treatment recommendations. ! Normal gene (-)
More informationGenetic Testing Patient Guide
Genetic Testing Patient Guide Over the last decade, pharmacogenetics has become increasingly significant to clinical practice. Psychiatric patients, in particular, may benefit from pharmacogenetic testing
More informationArticle. Reference. Applications of CYP450 Testing in the Clinical Setting. SAMER, Caroline Flora, et al.
Article Applications of CYP450 Testing in the Clinical Setting SAMER, Caroline Flora, et al. Abstract Interindividual variability in drug response is a major clinical problem. Polymedication and genetic
More informationGenetic Testing for Mental Health Conditions
Genetic Testing for Mental Health Conditions Policy Number: Original Effective Date: MM.02.026 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/01/2015 Section: Medicine
More informationPharmacogenomics and Clinical Practice: Ready for Prime Time?
Pharmacogenomics and Clinical Practice: Ready for Prime Time? Manju T. Beier, Pharm D, CGP, FASCP Chief Scientific Officer Natural Molecular Testing Corp. Adjunct Clinical Associate Professor of Pharmacy
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationDetox and Methylation Mutation Report for Customer: f21c5b7c-d7e5-4fae-969c-5e
NutraHacker Detox and Methylation Mutation Report for Customer: f21c5b7c-d7e5-4fae-969c-5e6925488206 Instructions: This FREE NutraHacker report contains detox and methylation mutations (single nucleotide
More informationBEHAVIORAL HEALTH GENOTYPING REPORT
Health, Sally; DOB: 09/05/1988 PAGE 1 OF 5 BEHAVIORAL HEALTH GENOTYPING REPORT Patient Name: Health, Sally Date Sample Collected: 06/27/14 DOB: 09/05/1988 Date Sample Received: 07/04/14 Lab ID Number:
More informationCONTRAINDICATIONS TABLE
CONTRAINDICATIONS TABLE Generic Name Brand Name Contraindications Amphetamine Salts Adderall, Adderall XR Hypersensitivity to amphetamine, dextroamphetamine, or other sympathomimetic amines Advanced arteriosclerosis
More informationImpact of CYP2C19 genetics on pharmacokinetic variability of escitalopram and sertraline - a study based on therapeutic drug monitoring data
Impact of CYP2C19 genetics on pharmacokinetic variability of escitalopram and sertraline - a study based on therapeutic drug monitoring data Ida Rudberg 2009 Department of Psychopharmacology Diakonhjemmet
More informationOver the last 50 years, the scientific and medical community has
Precision medicine and pharmacogenomics in community and primary care settings Over the last 50 years, the scientific and medical community has seen the field of pharmacogenomics and precision medicine
More informationPharmacogenetics: DNA analysis. to explain / predict. response to drug therapy. Maurizio Ferrari & Ron van Schaik
Maurizio Ferrari & Ron van Schaik Workshop IFCC Kuala Lumpur November 19, 2012 Predictive, Preventive and Personalized Medicine Part II: Pharmacogenetics l r.vanschaik@erasmusmc.nl Pharmacogenetics: DNA
More informationFalk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick
Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics Gerd Kullak-Ublick Division of Clinical Pharmacology and Toxicology Department of Internal Medicine University Hospital Zurich Freiburg, 8.
More informationClinical Implications of Pharmacogenetic Variation on the Effects of Statins
REVIEW ARTICLE Drug Saf 2011; 34 (1): 1-19 0114-5916/11/0001-0001/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Clinical Implications of Pharmacogenetic Variation on the Effects of Statins
More informationFORENSIC SCIENCE NEWSLETTER Forensic Pathology and Neuropathology. William A. Cox, M.D., FCAP.
FORENSIC PATHOLOGY FORENSIC SCIENCE NEWSLETTER Forensic Pathology and Neuropathology William A. Cox, M.D., FCAP www.forensicjournals.com June 1, 2016 The Safety of Newborn Infants who are Breast Fed by
More informationCYP2D6: mirtazapine 2001/2002/2003
CYP2D6: mirtazapine 2001/2002/200 Cl or = oral clearance,=c ss = steady state concentration, EM = extensive metaboliser, IM = intermediate metaboliser, MR = metabolic ratio, NS = non-significant, PM =
More informationDetox and Methylation Mutation Report for Customer: a-97dd-6604ce662da3
NutraHacker Detox and Methylation Mutation Report for Customer: 71666422-3218-464a-97dd-6604ce662da3 Instructions: This FREE NutraHacker report contains detox and methylation mutations (single nucleotide
More informationGan GG Department of Medicine University Malaya Medical Centre Kuala Lumpur
Gan GG Department of Medicine University Malaya Medical Centre Kuala Lumpur outline Definitions Genetic polymorphisms and drugs therapy a)warfarin b) Mercaptopurine c) Methotrexate d) Clopidogrel e) others
More informationCytochrome P450 interactions
Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits
More informationCore Data Set CYP2D6 Metabolism
Core Data Set CYP2D6 Metabolism Oxidised metabolites seen in pre-clinical species Inhibitor Target CYP Isoform CLint (µl/min/mg protein) % Inhibition Control 12.5 - Furafylline 1A2 12.9 0 Sulfaphenoxazole
More informationMembership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4
A Closer Look at the Central Nervous System PRN Overview of the PRN The Central Nervous System Practice and Research Network (CNS PRN) provides a forum to encourage networking among pharmacists specializing
More information6/6/2018. Nalbuphine: Analgesic with a Niche. Mellar P Davis MD FCCP FAAHPM. Summary of Advantages. Summary of Advantages
Nalbuphine: Analgesic with a Niche Mellar P Davis MD FCCP FAAHPM 1 Summary of Advantages Safe in renal failure- fecal excretion Analgesia equal to morphine with fewer side effects Reduced constipation
More informationPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
(2004) 9, 442 473 & 2004 Nature Publishing Group All rights reserved 1359-4184/04 $25.00 www.nature.com/mp FEATURE REVIEW Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic
More informationNicotine dependence treatment: A translational research approach
Washington University School of Medicine Digital Commons@Becker Presentations 2009: Translating Basic Science Findings to Guide Prevention Efforts 2009 Nicotine dependence treatment: A translational research
More information3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing
UP! UNDERSTANDING PHARMACOGENOMICS (PGX) Robert Pyatt Ph.D., Director Sanford Medical Genetics and Genomics Laboratories and Associate Professor, Dept of Internal Medicine, University of South Dakota April
More informationCytokrom P450 (CYP) Hepatic Drug Metabolism. Medicines in plasma. Plasma concentration of a medicine. Eva Brittebo Dept Pharmaceutical Biosciences
Hepatic Drug Metabolism Eva Brittebo Dept Pharmaceutical Biosciences Background Cytochrome P450 (CYP) Liver metabolism Liver toxicity Inhibition and induction Polymorphism 15-05-13 2 Plasma concentration
More informationGenetic Testing for Pharmacogenetics
Genetic Testing for Pharmacogenetics MP9479 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below (1.0 and 3.0) Additional Information: None Prevea360 Health Plan
More informationCardiovascular Health. Heart Disease / Atrial Fibrillation. Hypertension
P: 1300 688 522 E: info@nutripath.com.au A: PO Box 442 Ashburton VIC 3142 TEST PATIENT Sex : D Collected : 00-00-0000 111 ROAD TEST SUBURB AB : 00000000 UR#:0000000 TEST PHYSICIAN DR JOHN DOE 111 CLINIC
More informationMedical Policy. MP Genetic Testing for Mental Health Conditions
Medical Policy MP 2.04.110 BCBSA Ref. Policy: 2.04.110 Last Review: 06/22/2017 Effective Date: 06/22/2017 Section: Medicine End Date: 06/26/2018 Related Policies 2.04.38 Cytochrome p450 Genotyping 2.04.82
More informationPharmacogenomics In Psychiatry. Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University. XGEN Group NIH PGRN
Pharmacogenomics In Psychiatry Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University XGEN Group NIH PGRN Why do we need biomarkers in drug therapy? Limited efficacy Adverse drug effects
More informationThrombosis Research active studies
Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility
More informationPharmacogenetics and Pharmacokinetics
Chapter 2 Pharmacogenetics and Pharmacokinetics Mauro Saivezzo/ShutterStock, Inc. L earning O bjectives Upon completion of this chapter, the student will be able to: 1. Recognize the influence of genetic
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytochrome p450 Genotyping Page 1 of 24 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: See Also: Cytochrome p450 Genotyping Genetic Testing for Helicobacter
More informationGUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS
City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE
More information2015 Annual Physician Notice
0 Annual Physician Notice The Office of Inspector General (OIG) recommends clinical laboratories send notices to physicians and other providers who use their services, at least once a year, to inform the
More informationPharmacogenomics: Genetic variations in drug metabolism and utilization. Disclosure
Pharmacogenomics: Genetic variations in drug metabolism and utilization Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP President, Fitzgerald Health Education Associates, North Andover,
More information2/28/2010. Pharmacogenomics and the Asian Population. Limited efficacy/response to drugs already on the market
Pharmacogenomics and the Asian Population Majority are medication related Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, February 27, 20 Limited efficacy/response
More informationClozapine Case 1 The Relevance of CYP Jose de Leon, MD
Clozapine Case 1 The Relevance of CYP 12-18-15 Jose de Leon, MD 1. Clozapine Case 1 J Clin Psychiatry 1996;57:175-176 http://www.ncbi.nlm.nih.gov/pubmed/8601555 Educational Objectives At the conclusion
More information5/2/18. After this class students should be able to: Stephanie Moon, Ph.D. - GWAS. How do we distinguish Mendelian from non-mendelian traits?
corebio II - genetics: WED 25 April 2018. 2018 Stephanie Moon, Ph.D. - GWAS After this class students should be able to: 1. Compare and contrast methods used to discover the genetic basis of traits or
More informationSummary of the risk management plan (RMP) for Wakix (pitolisant)
EMA/794885/2015 Summary of the risk management plan (RMP) for Wakix (pitolisant) This is a summary of the risk management plan (RMP) for Wakix, which details the measures to be taken in order to ensure
More informationNovel Genetic Approach for the Identification of Placebo Responders A Viable Strategy for Reducing Clinical Trial Size, Cost and Time to Market
Novel Genetic Approach for the Identification of Placebo Responders A Viable Strategy for Reducing Clinical Trial Size, Cost and Time to Market Executive Summary 1. We identified a biomarker for placebo
More informationSMOKING AND DRUG INTERACTIONS
Medicines Information Centre Pharmacy Department UK Medicines Information SMOKING AND DRUG INTERACTIONS Introduction Smoking rates are significantly higher among people with mental health problems. It
More informationDrugs, The Brain, and Behavior
Drugs, The Brain, and Behavior John Nyby Department of Biological Sciences Lehigh University What is a drug? Difficult to define Know it when you see it Neuroactive vs Non-Neuroactive drugs Two major types
More informationPRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist
PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines
More informationCognitive, affective, & social neuroscience
Cognitive, affective, & social neuroscience Time: Wed, 10:15 to 11:45 Prof. Dr. Björn Rasch, Division of Cognitive Biopsychology University of Fribourg 1 Content } 5.11. Introduction to imaging genetics
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationMETHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE
METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE Work with methadone clinic staff to coordinate the methadone taper, with the transition to buprenorphine/naloxone:
More informationCYP2D6: Genotypes, Phenotypes, and Genetic Testing
CYP2D6: Genotypes, Phenotypes, and Genetic Testing In 1975, several laboratory scientists at St. Mary s Hospital Medical School in London each ingested a 40 mg dose of debrisoquine, an antihypertensive
More informationCOMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK
COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics
More informationVariation in drug responses & Drug-Drug Interactions
Variation in drug responses & Drug-Drug Interactions 1 Properties of an Ideal Drug Effective Safety Selective Reversible Action Predictable Freedom from drug interactions Low cost Chemically stable Sources
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationA unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure
A unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure Sylvain Goutelle, Michel Tod, Laurent Bourguignon, Nathalie Bleyzac,
More informationBasics of Pharmacology
Basics of Pharmacology Pekka Rauhala Transmed 2013 What is pharmacology? Pharmacology may be defined as the study of the effects of drugs on the function of living systems Pharmacodynamics The mechanism(s)
More information